New Treatments & Clinical Trials for Leukemia

Leukemia is cancer of the blood-forming cells. It includes acute forms that develop quickly and chronic forms that progress slowly. Treatment has advanced dramatically — many people with chronic forms now live normal lifespans on targeted pills, and cure rates for some acute leukemias now exceed 90% with chemotherapy and newer immune-based therapies.

What's actually going on in research

Trials are testing CAR-T cell therapies for hard-to-treat leukemias, bispecific antibodies that redirect immune cells to attack cancer, and targeted drugs like BTK inhibitors and menin inhibitors. Researchers are also studying minimal residual disease monitoring to catch relapse earlier and testing transplant alternatives for older patients who can't tolerate intensive chemotherapy.

What to know before you search

Eligibility typically depends on leukemia subtype, genetic markers, number of prior treatments, fitness for chemotherapy, and whether measurable disease remains after initial therapy.

What types of trials are currently open

• Targeted therapy trials — Testing pills that attack specific mutations in leukemia cells, such as FLT3 or IDH inhibitors. These often combine with chemotherapy or replace it in older patients.
• Immunotherapy trials — Testing CAR-T cells, bispecific antibodies, or checkpoint inhibitors that help the immune system recognize and kill leukemia cells.
• Chemotherapy trials — Testing new combinations or schedules of chemotherapy drugs, often aiming to reduce side effects while maintaining cure rates.
• Transplant trials — Studies of stem cell transplant timing, donor matching, and methods to prevent graft-versus-host disease after transplant.
• Maintenance trials — Testing drugs taken after initial treatment to prevent relapse, particularly targeted pills that may extend remission in acute leukemias.